Cathepsin K in treatment monitoring following intravenous zoledronic acid

Jahn,Oliver; Wex,Thomas; Klose,Silke; Kropf,Siegfried; Adolf,Daniela; Piatek,Stefan

doi:10.3892/br.2014.360

Cathepsin K in treatment monitoring following intravenous zoledronic acid

Authors:
- Oliver Jahn
- Thomas Wex
- Silke Klose
- Siegfried Kropf
- Daniela Adolf
- Stefan Piatek
View Affiliations

Affiliations: Department of Trauma Surgery, Otto von Guericke University, D‑39120 Magdeburg, Germany, Department of Gastroenterology, Hepatology and Infectious Diseases, Otto von Guericke University, D‑39120 Magdeburg, Germany, Department of Nephrology, Hypertension, Endocrinology and Metabolic Diseases, Otto von Guericke University, D‑39120 Magdeburg, Germany, Department of Biometry and Medical Informatics, Otto von Guericke University, D‑39120 Magdeburg, Germany
Published online on: September 10, 2014 https://doi.org/10.3892/br.2014.360
Pages: 915-917

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Cathepsin K (CatK) is mainly expressed by osteoclasts and plays an important role in bone resorption. As CatK is expressed and secreted by osteoclasts during active bone resorption, it may be a useful and specific biochemical marker of osteoclastic activity. Therefore, CatK serum levels were studied for monitoring the treatment of females with postmenopausal osteoporosis by zoledronic acid. The serum CatK levels were determined in nine postmenopausal females before and after 3, 6 and 12 months of treatment. The levels were significantly reduced after 3 and 6 months (P<0.05), whereas they returned to baseline after 1 year. Taken together, the serum level of CatK may be suitable for monitoring anti‑osteoporotic therapy in association with treatment response.

View Figures

View References

1	No authors listed. Consensus Development Conference on Osteoporosis. Hong Kong, April 1–2, 1993. Am J Med. 95:S1–S78. 1993.PubMed/NCBI
2	No authors listed. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organ Tech Rep Ser. 843:1–129. 1994.PubMed/NCBI
3	Delmas PD: Markers of bone turnover for monitoring treatment of osteoporosis with antiresorptive drugs. Osteoporos Int. 11(Suppl 6): S66–S76. 2000. View Article : Google Scholar : PubMed/NCBI
4	Delmas PD, Eastell R, Garnero P, Seibel MJ and Stepan J; Committee of Scientific Advisors of the International Osteoporosis Foundation. The use of biochemical markers of bone turnover in osteoporosis. Committee of Scientific Advisors of the International Osteoporosis Foundation. Osteoporos Int. 11(Suppl 6): S2–S17. 2000. View Article : Google Scholar : PubMed/NCBI
5	Delmas PD, Hardy P, Garnero P and Dain M: Monitoring individual response to hormone replacement therapy with bone markers. Bone. 26:553–560. 2000. View Article : Google Scholar : PubMed/NCBI
6	Seibel MJ: Biochemical markers of bone remodeling. Endocrinol Metab Clin North Am. 32:83–113. 2003. View Article : Google Scholar : PubMed/NCBI
7	Szulc P: The role of bone turnover markers in monitoring treatment in postmenopausal osteoporosis. Clin Biochem. 45:907–919. 2012. View Article : Google Scholar : PubMed/NCBI
8	Hadji P, Klein S, Gothe H, Häussler B, Kless T, Schmidt T, Steinle T, Verheyen F and Linder R: The epidemiology of osteoporosis - Bone Evaluation Study (BEST): an analysis of routine health insurance data. Dtsch Arztebl Int. 110:52–57. 2013.PubMed/NCBI
9	Troen BR: The role of cathepsin K in normal bone resorption. Drug News Perspect. 17:19–28. 2004. View Article : Google Scholar
10	Inaoka T, Bilbe G, Ishibashi O, Tezuka K, Kumegawa M and Kokubo T: Molecular cloning of human cDNA for cathepsin K: novel cystein protease predominantly expressed in bone. Biochem Biophys Res Commun. 206:89–96. 1995. View Article : Google Scholar : PubMed/NCBI
11	Gelb BD, Shi G, Chapman HA and Desnick RJ: Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency. Science. 273:1236–1238. 1996. View Article : Google Scholar : PubMed/NCBI
12	Saftig P, Hunziker E, Wehmeyer O, Jones S, Boyde A, Rommerskirch W, Moritz JD, Schu P and von Figura K: Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin-K-deficient mice. Proc Natl Acad Sci USA. 95:13453–13458. 1988. View Article : Google Scholar : PubMed/NCBI
13	Henriksen K, Tanko LB, Qvist P, Delmas PD, Christiansen C and Karsdal MA: Assessment of osteoclast number and function: application in the development of new and impoved treatment modalities for bone diseases. Osteoporos Int. 18:681–685. 2007. View Article : Google Scholar : PubMed/NCBI
14	Dachverband Osteologie e.v. DVO-Leitlinie 2009 zur Prophylaxe, Diagnostik und Therapie der Osteoporose bei Erwachsenen. Osteologie. 18:304–328. 2009.
15	Adolf D, Wex T, Jahn O, Riebau C, Halangk W, Klose S, Westphal S, Amthauer H, Winckler S and Piatek S: Serum cathepsin K levels are not suitable to differentiate women with chronic bone disorders such as osteopenia and osteoporosis from healthy pre- and postmenopausal women. Maturitas. 71:169–172. 2012. View Article : Google Scholar : PubMed/NCBI
16	Holzer G, Noske H, Lang T, Holzer L and Willinger U: Soluble cathepsin K: a novel marker for the prediction of nontraumatic fractures? J Lab Clin Med. 146:13–17. 2005. View Article : Google Scholar : PubMed/NCBI
17	Meier C, Meinhard U, Greenfield JR, De Winter J, Nguyen TV, Dunstan CR and Seibel MJ: Serum cathepsin K concentrations reflect osteoclastic activity in women with postmenopausal osteoporosis and patients with Paget’s disease. Clin Lab. 52:1–10. 2006.PubMed/NCBI
18	Munoz-Torres M, Reyes-Garcia R, Mezquita-Raya P, Fernandes-Garcia D, Alonso G, de Luna JD, Ruiz-Requena ME and Escobar-Jimenez F: Serum cathepsin K as a marker of bone metabolism in postmenopausal women treated with alendronate. Maturitas. 64:188–192. 2009. View Article : Google Scholar : PubMed/NCBI